Science Corporation Raises $400M to Expand PRIMA Access
Science Corporation is putting a commercial vision-restoration device and a living-neuron research program on the same financing plan. The Alameda, California company announced a $400M Series D on November 17, 2026, backing wider European access to PRIMA, preparation for a possible US launch and further development of its biohybrid neural interface.
The financing includes Khosla Ventures, Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech, among others. Science says cumulative funding since its founding in 2021 exceeds $900M. TechCrunch reports a $3.5B valuation, citing a person familiar with the financing.
Co-founder and CEO Max Hodak leads the company with co-founder and CSO Alan Mardinly and co-founder Emma Zhou, Director of BCI Research. The operating assignment stretches across clinical access, manufacturing and research, with different milestones for each. For investors following neural engineering, Science offers a particularly concrete view of how much work begins after a device earns permission to enter a market.
PRIMA brings the clinic into the financing story
PRIMA combines a retinal implant with glasses containing a camera and projector. The implant's 378 light-powered pixels convert projected light into electrical signals that stimulate retinal cells. Science designed the system to help restore central vision in people blinded by certain forms of late-stage macular degeneration, where damage to the retina can take away the ability to read letters, numbers and words.
That mechanism matters commercially because the product lives inside a treatment process. Implantation, clinical assessment and support belong to the experience of receiving PRIMA. Understanding the hardware alone leaves out the people and institutions needed to make it useful, and it leaves out much of the work Science is now financing.
Science announced PRIMA's European commercial launch and CE marking on July 22. At launch, the company said country-specific reimbursement applications and clinical-site activations were underway. Those are consequential details for an operator: authorization creates the opportunity to serve patients, while local care arrangements help determine how that opportunity becomes access.
The current PRIMA site says the device is CE marked in the European Union and registered for supply in the United Kingdom. Availability remains specific to geography and indication. A European launch therefore gives Science a commercial starting point, with expansion still requiring practical work country by country.
The US pathway carries its own timetable
Science intends to use the Series D to prepare PRIMA for the United States while pursuing Food and Drug Administration approval through the Humanitarian Device Exemption pathway. That preparation sits alongside the European expansion rather than following a single worldwide launch calendar. A device company can be serving one market while still doing the regulatory work required to enter another.
PRIMA has received Humanitarian Use Device designations for an advanced geographic-atrophy patient subset and for Stargardt disease. Science's announcement explains that FDA review and approval through an HDE are still required. The FDA describes designation and marketing review as separate steps, a distinction that belongs beside any discussion of US expansion.
For a financing reader, this creates a useful way to interpret the use of proceeds. Science is paying for the preparation around a potential US launch before the final regulatory outcome is known. The announcement gives no approved US launch date, and the current product site says PRIMA has not received approval for sale there.
The resulting operating picture is demanding without needing embellishment. European access and US regulatory preparation draw on overlapping engineering, clinical and operational capabilities, but their progress is measured differently. More financing lets Science keep those assignments moving together while patients and clinical teams remain dependent on the rules of their own markets.
A second research horizon sits beside PRIMA
Science's biohybrid program pursues an interface that combines engineered living neurons with electronics to connect with the brain's own circuitry. The architecture uses light to stimulate modified neurons and electrodes to record activity. It is a separate development program from the PRIMA retinal system, with its own research questions and clinical ambitions.
The Series D announcement commits substantial further investment to that program, as well as expansion of research, manufacturing and operational infrastructure. This puts the investment thesis across two horizons: delivery of an existing vision-restoration technology and development of a different way to interface with the brain. The financing disclosure does not specify how the proceeds will be divided between them.
That breadth is part of Science's organizational identity. The company describes in-house capabilities spanning transistor fabrication, cell editing and multidisciplinary neural engineering. Its Foundry also supplies components and infrastructure for other researchers, adding another relationship between the company's internal work and the wider field.
Science's leaders will have to evaluate these programs on their own terms. Progress in the biohybrid laboratory cannot stand in for progress in European treatment access, and success in one program does not establish clinical results for the other. Each program gives Science a different set of people to serve and evidence to produce as the organization grows.
Financing the organization around the device
The Series D follows Science's $230M Series C in March. The earlier financing already emphasized PRIMA commercialization and research infrastructure. November's round arrives after the European commercial launch, making access and operational expansion more immediate parts of the company's capital needs.
Science's current leadership includes President Darius Shahida, EVP of Engineering Nevada Sanchez and Chief Medical Officer for Ophthalmology Frank Brodie. Alongside the co-founders, those roles show the range of disciplines inside the business. Science also lists offices in Research Triangle Park, North Carolina, and Paris, in addition to its Alameda headquarters.
The company has not disclosed a lead investor for the new round, a detailed spending allocation or current PRIMA revenue in its announcement. Tenet Healthcare's participation establishes a financial relationship; the release does not announce a treatment-site or distribution agreement with Tenet. Keeping those boundaries clear makes the disclosed operating plan easier to assess.
Across Europe, Science is now supporting the arrangements through which an implant becomes something a patient can actually receive. At the same time, Science has a US regulatory pathway to pursue and its biohybrid researchers have a different interface to develop. The financing follows all three groups into work whose results will arrive on different calendars, sometimes in a laboratory and sometimes in the clinic where somebody is learning to read again.
Frequently Asked Questions
What work remains between PRIMA’s European launch and wider patient access?
Science identified country-specific reimbursement applications and clinical-site activation as part of its European launch. The Series D is intended to accelerate availability, but the financing announcement does not establish that all local reimbursement and treatment arrangements are complete.
Does PRIMA’s Humanitarian Use Device designation mean it can be sold in the United States?
No. HUD designation is a step toward a separate Humanitarian Device Exemption review. Science says it is pursuing FDA approval, and PRIMA’s current product site does not list US commercial approval.
How does PRIMA differ from Science’s biohybrid neural interface?
PRIMA uses a retinal implant and camera/projector glasses to stimulate retinal cells. The biohybrid program combines engineered living neurons with electronics to connect with brain circuitry and is a separate research program.
What will Science use the Series D financing for?
Science plans to expand PRIMA availability in Europe, prepare a possible US launch while pursuing approval, and expand research, manufacturing and operations. It also plans further investment in its biohybrid program; a detailed allocation was not disclosed.
How should readers interpret Science’s reported valuation and total funding?
Science reports more than $900M raised since its founding in 2021. The $3.5B valuation comes from TechCrunch’s reporting rather than the company’s financing release, and the two figures describe different things.
Where the Money Moved
The intelligence briefing of the innovation economy. Funding, M&A, debt and fund closes, read as market signal rather than deal announcements.
Subscribe to Where the Money Moved